Work

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

Year: 2009
Type: review
Abstract: The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review.
Language: English
Open Access status: bronze
OpenAlex ID: W2161437969
FWCI: 2.781
Cites: 72
Cited by: 166
Related to: 10